Exicure Discloses Substantial Doubt About Going Concern, Nasdaq Non-Compliance, and Material Weaknesses
XCUR sits 20% above its 52-week low of $2.627.
Summary
Exicure's Q1 2026 report highlights severe financial distress with dwindling cash, an explicit going concern warning including bankruptcy risk, a Nasdaq non-compliance notice, and material weaknesses in internal controls.
Key Events · Corporate Governance and Compliance · XCUR
-
Substantial Doubt About Going Concern
Cash and cash equivalents declined to $2.6 million as of March 31, 2026. Management believes existing cash is insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and explicitly mentioning potential bankruptcy or cessation of operations.
-
Nasdaq Non-Compliance Notice
The company received a notice on May 28, 2026, from Nasdaq for non-compliance with listing rules due to the delayed filing of this Quarterly Report on Form 10-Q.
-
Material Weaknesses in Internal Controls
Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, citing material weaknesses related to the review of non-routine accounting activities and the design and implementation of controls across accounting and IT processes.
-
Escalating Legal Liabilities
Exicure faces a lawsuit for approximately $0.7 million in unpaid rent for its Redwood City facility, which it vacated on April 15, 2026. Additionally, a former employee's breach of contract claim, for which $0.25 million was accrued, now includes demands for significantly higher damages due to accrued interest under the IWPCA.
Analysis · XCUR · Life Sciences
Exicure's latest quarterly report reveals a critical financial state, with cash and cash equivalents dropping to $2.6 million as of March 31, 2026, down from $3.7 million at year-end 2025. The company explicitly states substantial doubt about its ability to continue as a going concern, warning of potential bankruptcy or cessation of operations if additional financing cannot be secured. This dire financial outlook is compounded by a Nasdaq non-compliance notice received on May 28, 2026, for the delayed filing of this very 10-Q, posing an immediate delisting risk. Furthermore, management identified material weaknesses in internal controls over financial reporting, indicating significant governance and operational challenges. The company also faces escalating legal liabilities, including a lawsuit for $0.7 million in unpaid rent and a former employee's claim for potentially significantly higher damages due to accrued interest.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.2% of the 386 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.51%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1M. The 52-week trading range was $2.63 to $10.80. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.